Acetazolamide in lithium-induced nephrogenic diabetes insipidus (NDI).

The effect of acetazolamide on lithium-induced Nephrogenic Diabetes Insipidus in patients with affective disorders: a pilot study

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613000195752

Enrollment

Registered

2013-02-19

Start date

2013-05-01

Completion date

2013-05-22

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Lithium is an effective drug for controlling various mood disorders. However it is frequently associated with the development of nephrogenic diabetes inspidus - where the individual is unable to concentrate their urine and so have an increased thirst and pass large quantities of urine. This can be modified by the use of amiloride which blocks the action of lithium in the kidney and corrects the NDI. Acetazolamide also alters kidney handling of lithium and may be more effective in correcting the NDI. We wish to test this in a group of individuals on lithium therapy.

Interventions

In this pilot study we will evaluate the efficacy of acetazolamide in the treatment of lithium-induced NDI. Acetazolamide will be commenced at 250mg orally once a day for 7 days, then increased to 250mg orally twice a day for the 2nd week, then as tolerated to 500mg orally twice a week for weeks 3 & 4. If the higher dose is not tolerated, the dose will be lowered back to the tolerated oral dose.Total duration of treatment is 4 weeks.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

stable patients treated with lithium for an affective disorder men and women age > 18 years evidence of lithium- induced nephrogenic diabetes insipidus

Exclusion criteria

pregnancy diabetes mellitus underlying renal disorders significant cardiac/pulmonary comorbidity heart rhythm disorders side effects of lithium treatment treatment with hydrochlorothiazide or amiloride in the preceding 2 weeks concomitant treatment with other diuretics hypotension (systolic blood pressure < 100 mm Hg) renal insufficiency hypo/hyperkalemia hypercalcaemia hypo/hyperthyroidism

Outcome results